Pharmaceutical and healthcare market in Poland 2017

Market analysis and development forecasts for 2017-2022

Industry Report

Pharmaceutical and healthcare market in Poland 2017

Market analysis and development forecasts for 2017-2022

This product is also available in Polish

Product details

Price:

2 400

Choose language

You don't have to wait. The content will be accessible online at the My PMR account.

Pharmaceutical and healthcare market in Poland 2017

Market analysis and development forecasts for 2017-2022

This document includes comprehensive analysis of the pharmaceutical and healthcare market in Poland, data on pharmacy and hospital sales, details on the key categories of ATC drugs, analysis of epidemiological trends and profiles and listings of major manufacturers and the best-selling products. It presents in-depth market development forecasts for the entire market during the period 2017-2022, as well as for each ATC category, as well as a look at current consumer preferences with regard to purchasing medicines and using specific health services.

Subscription: 12 months
Publication date: September 2016
Other versions: Polish
Delivery: Online with easy export (PDF, PPT, XLS, DOC)
Sector: Pharma
Country: Poland
Pages: 349

Do you need assistance?

Phone: +48 12 340 51 30

Email: info@pmrcr.com

Description

Description

This report presents complete information and in-depth analysis of the Polish pharmaceutical market, broken down into the pharmacy and hospital segments and organised by category of ATC medicine. It contains information on all major manufacturers and best-selling products among Poland’s consumers. 

 

The document includes analysis of the Polish healthcare segment, according to key aspects such as: total numbers of public and private hospitals, number of beds at each facility, the number of doctors by specialisation and the total value of health care spending in Poland. 

 

Additional key elements of this report include pharmaceutical market value and development forecasts for the period 2017 to 2022 as well as information illustrating consumer preferences when purchasing medicines and choosing specific health care services.

 

What is the content of PMR’s report on pharmaceutical and healthcare market in Poland?

 

Use this report to learn more about:

  • Value of the entire pharmaceutical market and of each category of ATC pharmaceuticals
  • Market development forecasts for the period 2016 to 2021 – for the overall market and for several ATC categories 
  • Major pharmaceutical manufacturers operating in Poland
  • Best-selling drugs and dietary supplements in Poland
  • The current sales totals for the most widely-used categories of ATC drugs, as well as sales forecasts for the coming years
  • Barriers and supporting factors that influence the development of the entire market and each individual category of medicines and health services
  • Detailed analysis of the current legal status, as well as possible future legal changes

  • Comprehensive data on the reimbursement process in Poland, including the application, refund rules, major practical problems, expenses for the refund, products of the highest refund to open reimbursement (pharmacy market), chemotherapy and drug programs

  • Analysis of generic substitution

  • List of drug programs existing in Poland, along with active substances

  • Poland’s national reimbursement policy, with presentation and impact analysis of the most recent changes to reimbursement lists and possible modifications in the future

  • Total spending of NFZ on medication refunds, including ATC classification category, the voivodship and the level of payment required from the patient
  • Epidemiological trends in Poland, including data describing the most common diseases and the most common cause of death in Poland
  • Consumer behaviour related to the purchase of drugs and use of specific healthcare services.

 

Who benefits from the analysis? 

 

PMR recommends this document to managerial staff and operational-level employees at marketing, sales, strategy and development divisions of the following companies:

  • Financial institutions interested in the pharmaceutical and healthcare market in Poland, including banks, brokerage houses and investment funds
  • Consulting companies, research agencies, governments and research bodies that monitor the Polish pharmaceutical and medical industry
  • Marketing agencies serving pharmaceutical and medical companies
  • Drug manufacturers and producers operating in the market
  • Pharmaceutical distributors 
  • Hospitals, both public and non-public
  • Non-hospital providers of healthcare services.

 

Why to buy the report? 

 

This report is especially helpful to those engaged in:

  • Monitoring the development and changes taking place in Poland’s pharmaceutical and healthcare market
  • Planning a new pharmaceutical or medical investment
  • Making decisions regarding financial support for entities operating in this market
  • Development of a product portfolio using ATC identification to determine categories that offer the highest growth potential
  • Analysis of potential investment and credit risks in this market
  • Performing merger or acquisition transactions 
  • Analysis of current business operations, performance and growth plans of the competition
  • Preparation of corporate development strategies and budgets based on reliable forecasts for market development over the next five years
  • Estimating demand for various categories of medicines and types of healthcare services
  • Preparing to enter the pharmaceutical and medical market in Poland
  • Beginning business operations in new segments of this market.

What is the content of the report?

Use this report to learn more about:

  • Value of the entire pharmaceutical market and of each category of ATC pharmaceuticals
  • Market development forecasts for the period 2017 to 2022 – for the overall market and for several ATC categories 
  • Major pharmaceutical manufacturers operating in Poland
  • Best-selling drugs and dietary supplements in Poland
  • The current sales totals for the most widely-used categories of ATC drugs, as well as sales forecasts for the coming years
  • Barriers and supporting factors that influence the development of the entire market and each individual category of medicines and health services
  • Detailed analysis of the current legal status, as well as possible future legal changes

  • Comprehensive data on the reimbursement process in Poland, including the application, refund rules, major practical problems, expenses for the refund, products of the highest refund to open reimbursement (pharmacy market), chemotherapy and drug programs

  • Analysis of generic substitution

  • List of drug programs existing in Poland, along with active substances (January 2016)

  • Poland’s national reimbursement policy, with presentation and impact analysis of the most recent changes to reimbursement lists and possible modifications in the future

  • Total spending of NFZ on medication refunds, including ATC classification category, the voivodship and the level of payment required from the patient
  • Epidemiological trends in Poland, including data describing the most common diseases and the most common cause of death in Poland
  • Consumer behaviour related to the purchase of drugs and use of specific healthcare services.

Who benefits from the analysis?

PMR recommends this document to managerial staff and operational-level employees at marketing, sales, strategy and development divisions of the following companies:

  • Financial institutions interested in the pharmaceutical and healthcare market in Poland, including banks, brokerage houses and investment funds
  • Consulting companies, research agencies, governments and research bodies that monitor the Polish pharmaceutical and medical industry
  • Marketing agencies serving pharmaceutical and medical companies
  • Drug manufacturers and producers operating in the market
  • Pharmaceutical distributors 
  • Hospitals, both public and non-public
  • Non-hospital providers of healthcare services.

Why to buy the report?

This report is especially helpful to those engaged in:

  • Monitoring the development and changes taking place in Poland’s pharmaceutical and healthcare market
  • Planning a new pharmaceutical or medical investment
  • Making decisions regarding financial support for entities operating in this market
  • Development of a product portfolio using ATC identification to determine categories that offer the highest growth potential
  • Analysis of potential investment and credit risks in this market
  • Performing merger or acquisition transactions 
  • Analysis of current business operations, performance and growth plans of the competition
  • Preparation of corporate development strategies and budgets based on reliable forecasts for market development over the next five years
  • Estimating demand for various categories of medicines and types of healthcare services
  • Preparing to enter the pharmaceutical and medical market in Poland
  • Beginning business operations in new segments of this market.
Table of Contents

Table of Contents

Graphs and Tables

Graphs and Tables

Infographic

Infographic

Product details

Price:

2 400

Select languages:

Choose language

You don't have to wait. The content will be accessible online at the My PMR account.

Subscription: 12 months
Publication date: January 2018
Other versions: Polish
Delivery: Online with easy export (PDF, PPT, XLS, DOC)
Sector: Pharmaceuticals & Parapharmaceuticals
Country: Poland

Do you need assistance?

Phone: +48 12 340 51 30

Email: support@pmrcorporate.com

Clients' Testimonials

 We are a long-standing subscriber of PMR’s information services, and specifically its pharmaceutical and healthcare market news bulletins.

We appreciate the reliability of the information provided,and the high standards of data analysis offered by PMR.    

Prezes Zarządu

PHOENIX Pharma Polska Sp. z o. o

I have been using PMR reports in my daily work for over 3 years. They are a source of consolidated knowledge based on the relevant indicators. At the same time I value our cooperation as an expert in the Health Care market in Poland. Your forecasts are important to us when working on marketing and promotional strategies.

Head of Sales and Marketing

Roche Diagnostic Polska Sp. z o.o.

Standard - license option entitles Client to make use of the product for a maximum of 2 persons indicated in the purchase process

Standard Plus - license option entitles Client to make use of the product for between 3 and 9 persons indicated in the purchase process

Corporate - license option entitles Client to make use of the product for between 10 and an unlimited number of persons indicated in the purchase process